Retina World Congress

Videos

Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.

Miniature telescope in dry AMD: Surgical implantation improves vision for patients with late-stage AMD

Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.

Evaluating effect of central subfield thickness, volatility on visual acuity in clinical trials for nAMD

Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.

Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO

Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.

Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.

Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema

David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.

Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy

Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.

Hypersonic vitrectomy: Novel technology for vitreous removal

While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.

Carl Regillo, MD, outlines latest results of KSI-301 clinical trial

In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.